The Journal of Allergy and Clinical Immunology
Volume 117, Issue 6 , Pages 1292-1302 , June 2006

Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report

  • Amy D. Klion, MD

      Affiliations

    • From the Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda
    • Corresponding Author InformationReprint requests: Amy D. Klion, MD, Bldg 4, Rm 126, National Institutes of Health, 4 Center Dr, Bethesda, MD 20892.
    • ,
  • Bruce S. Bochner, MD

      Affiliations

    • Johns Hopkins Asthma and Allergy Center, Baltimore
    • ,
  • Gerald J. Gleich, MD

      Affiliations

    • Departments of Dermatology and Medicine, University of Utah, Salt Lake City
    • ,
  • Thomas B. Nutman, MD

      Affiliations

    • From the Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda
    • ,
  • Marc E. Rothenberg, MD, PhD

      Affiliations

    • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati
    • ,
  • Hans-Uwe Simon, MD, PhD

      Affiliations

    • Department of Pharmacology, University of Bern
    • ,
  • Michael E. Wechsler, MD

      Affiliations

    • Harvard Medical School, Pulmonary and Critical Care Division, Brigham and Women's Hospital, Boston
    • ,
  • Peter F. Weller, MD

      Affiliations

    • Harvard Medical School, Department of Medicine, Beth Israel Deaconess Medical Center, Boston
    • ,
  • the Hypereosinophilic Syndromes Working Group

      Affiliations

    • The members of the Hypereosinophilic Syndromes Working Group are shown in the Acknowledgments.

Received 19 September 2005 ,Revised 22 February 2006 ,Accepted 24 February 2006.

References 

  1. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med. 1968;68:1220–1229
  2. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759–2779
  3. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol. 2004;77:82–85
  4. Roufosse F, Cogan E, Goldman M. Recent advances in the pathogenesis and management of hypereosinophilic syndromes. Allergy. 2004;59:673–689
  5. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A novel tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–1214
  6. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984;63:65–81
  7. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27:277–301
  8. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094–1100
  9. Lane SE, Watts R, Scott DG. Epidemiology of systemic vaculitis. Curr Rheumatol Rep. 2005;7:270–275
  10. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci. 2005;1051:121–131
  11. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol. 2004;113:11–28
  12. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med. 2004;351:940–941
  13. Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology. 2003;125:1660–1669
  14. Markowitz JE, Liacouras CA. Eosinophilic gastroenteritis. Gastroenterol Clinics. 2003;32:949–966
  15. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis and imatinib-responsiveness. Blood. 2003;101:4660–4666
  16. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341:1112–1120
  17. Roufosse F, Schandene L, Sibille C, Willard-Gallo K, Kennes B, Efira A, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol. 2000;109:540–548
  18. Pitini V, Arrigo C, Azzarello D, La Gattuta G, Amata C, Righi M, et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood. 2003;102:3456–3457
  19. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978;89:167–172
  20. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol. 2005;114:26–40
  21. Sakamoto K, Erdreich-Epstein A, deClerck Y, Coates T. Prolonged clinical response to vincristine treatment in two patients with hypereosinophilic syndrome. Am J Pediatr Hematol Oncol. 1992;14:348–351
  22. Schandene L, Roufosse F, de Lavareille A, Stordeur P, Efira A, Kennes B, et al. Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood. 2000;96:4285–4292
  23. Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349:2334–2339
  24. Klion AD, Law MA, Noel P, Haverty TP, Nutman TB. Safety and efficacy of the monoclonal anti-interleukin 5 antibody, SCH55700, in the treatment of patients with the hypereosinophilic syndrome. Blood. 2004;103:2939–2941
  25. Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol. 2004;113:115–119
  26. Kim YJ, Prussin C, Martin B, Law MA, Haverty TP, Nutman TB, et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL5 antibody SCH55700. J Allergy Clin Immunol. 2004;114:1449–1455
  27. Pitini V, Teti D, Arrigo C, Righi M. Alemtuzumab therapy for refractory hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol. 2004;127:477
  28. Sefcick A, Sowter D, DasGupta E, Russell NH, Byrne JL. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol. 2004;124:558–559
  29. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577–1578
  30. Klion AD, Robyn J, Akin C, Noel P, Brown M, Law MA, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2003;103:473–478
  31. Pardanani AD, Reeder TL, Porrata LF, Li CY, Tazelaar HD, Baxter Witzig TE, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101:391–397
  32. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell. 2003;3:459–469
  33. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18:1321–1331
  34. Ueno NT, Anagnostopoulos A, Rondon G, Champlin RE, Mikhailova N, Pankratova OS, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol. 2002;119:131–134
  35. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78:26–37
  36. Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol. 1997;36:1290–1297
  37. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JWC, Dadoniené J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44
  38. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with Churg-Strauss syndrome. Ann Intern Med. 1998;129:370–374
  39. Metzler C, Lamprecht P, Hellmich B, Reuter M, Arlt A-C, Gross WL. Leucoencephalopathy after treatment of Churg-Strauss syndrome with interferon a. Ann Rheum Dis. 2005;64:1242–1243
  40. Metzler C, Hellmich B, Gause A, Gross WL, de Groot K. Churg-Strauss syndrome—successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance therapy. Clin Exp Rheumatol. 2004;22(suppl 36):S52–S61
  41. Teitelbaum JE, Fox VL, Twarog FJ, Nurko S, Antonioli D, Gleich G, et al. Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone proprionate. Gastroenterology. 2002;122:1216–1225
  42. Markowitz JE, Spergel JM, Ruchelli E, Liacouras CA. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol. 2004;98:777–782
  43. Noel RJ, Putnam PE, Collins MH, Assa'ad AH, Guajardo JR, Jameson SC, et al. Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Gastroenterol Hepatol. 2004;2:568–575
  44. McNagny K, Graf T. Making eosinophils through subtle shifts in transcription factor expression. J Exp Med. 2002;195:F43–F47
  45. Yu C, Cantor AB, Yang H, Browne C, Wells RA, Fujiwara Y, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med. 2002;19:1387–1395
  46. Bochner BS. Verdict in the case of therapies versus eosinophils: the jury is still out. J Allergy Clin Immunol. 2004;113:3–9
  47. Druilhe A, Letuve S, Pretolani M. Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis. 2003;8:481–495

 The workshop was funded by Office of Rare Diseases Research of the National Institutes of Health, GlaxoSmithKline (GSK), and the American Partnership for Eosinophilic Disorders.Disclosure of potential conflict of interest: B. Bochner has consultant arrangements with GlaxoSmithKline. G. Gleich has consultant arrangements with GlaxoSmithKline, Ception Therapeutics, Eosynos, and Novartis Genentech; owns stock in Ception Therapeutics; is founder of Eosynos; has received grants from GlaxoSmithKline and Novartis Genentech; and is on the speakers' bureau for Novartis Genentech. M. Rothenberg has consultant arrangements with GlaxoSmithKline, Ception Therapeutics, and Cambridge Antibody Technology; owns stock in Ception Therapeutics; has received grants from Cambridge Antibody Technology; is on the speakers' bureau for Merck; and is an Honorarium from Tanox. H. Simon has consultant arrangements with GlaxoSmithKline, Greenford, United Kingdom, and has received grants from the Swiss National Science Foundation. M. Wechsler has consultant arrangements with Novartis Genentech; has received grants from Merck; and is on the speakers' bureau for Novartis Genentech and Merck. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(06)00520-3

doi: 10.1016/j.jaci.2006.02.042

The Journal of Allergy and Clinical Immunology
Volume 117, Issue 6 , Pages 1292-1302 , June 2006

Article Tools

* Image Usage & Resolution